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Abstract
 
Human immunodeficiency virus type 1 (HIV-1) fuses with cells after sequential interactions
between its envelope glycoproteins, CD4 and a coreceptor, usually CC chemokine receptor 5
(CCR5) or CXC receptor 4 (CXCR4). CMPD 167 is a CCR5-specific small molecule with
potent antiviral activity in vitro. We show that CMPD 167 caused a rapid and substantial (4–
200-fold) decrease in plasma viremia in six rhesus macaques chronically infected with simian
immunodeficiency virus (SIV) strains SIVmac251 or SIVB670, but not in an animal infected
with the X4 simian–human immunodeficiency virus (SHIV), SHIV-89.6P. In three of the
SIV-infected animals, viremia reduction was sustained. In one, there was a rapid, but partial,
rebound and in another, there was a rapid and complete rebound. There was a substantial delay
(
 
 
 
21 d) between the end of therapy and the onset of full viremia rebound in two animals. We
also evaluated whether vaginal administration of gel-formulated CMPD 167 could prevent
vaginal transmission of the R5 virus, SHIV-162P4. Complete protection occurred in only 2 of
11 animals, but early viral replication was significantly less in the 11 CMPD 167-recipients than
in 9 controls receiving carrier gel. These findings support the development of small molecule
CCR5 inhibitors as antiviral therapies, and possibly as components of a topical microbicide to
prevent HIV-1 sexual transmission.
Key words: HIV • AIDS • antiretroviral therapy • microbicide • chemokine receptor
 
Introduction
 
The primate immunodeficiency viruses HIV-1 and simian
immunodeficiency virus (SIV), and the chimeric, engi-
neered viruses known as simian–human immunodeficiency
viruses (SHIVs), all fuse with their target cells in a process
triggered by the sequential interaction of the viral envelope
glycoprotein complex with the CD4 receptor and a core-
ceptor (1, 2). The most important HIV-1 coreceptors are
CCR5 and CXCR4, with CCR5 being most commonly
used by viruses that dominate the early stages of infection
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Abbreviations used in this paper:
 
 AUC, area under the curve; HMC, hy-
droxymethyl cellulose; IC
 
50
 
, 50% inhibitory concentration; SHIV, simian–
human immunodeficiency virus; SIV, simian immunodeficiency virus.T
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(3–6). Indeed, the absence of CCR5 (homozygosity for the
defective CCR5-
 
 
 
32 allele) is strongly protective against
acquisition of HIV-1 infection, sexually or otherwise (7–
10). Several small molecules that bind to CCR5, including
SCH-C, SCH-D, and UK-427,857 are now in clinical de-
velopment to treat HIV-1 infection (11–17) (C. Hitch-
cock, personal communication). The licensing of enfu-
virtide (T-20) strongly supports the overall concept of
using entry inhibitors for this purpose (18, 19).
Entry inhibitors may also be useful as topically applied,
vaginal or rectal microbicides, or even for systemically ap-
plied prophylaxis, to prevent HIV-1 infection. There is an
urgent need to develop chemical methods of prevention,
particularly for covert use by women (20–22). The rationale
for including a CCR5-specific inhibitor in a microbicide
formulation is theoretically strong, because of the impor-
tance of CCR5 for establishment of HIV-1 infection (3–
10). Therefore, we have studied the effect of a small mole-
cule CCR5 inhibitor on both established viral infection in
rhesus macaques and on the transmission of a new infection.
CMPD 167 is a CCR5-specific receptor antagonist that is
no longer being developed as an antiviral drug for humans.
However, it is a potent inhibitor of HIV-1 infection in vitro
and its toxicology and pharmacology properties are appro-
priate for monkey analyses (23, 24). We used SIVmac251
and SIVB670 as the test viruses to study the effect of CMPD
167 on established viral infection. None of the available
CCR5-using SHIVs consistently generates an adequately
sustained level of plasma viremia during chronic infection
(25–27). SIV strains use CCR5 as their paramount corecep-
tor in primary T cells in vitro (28, 29), but their coreceptor
usage profile is broader on coreceptor-transfected cell lines
compared with HIV-1 (3–6). For vaginal challenge studies,
we used SHIV-162P4, which exclusively uses CCR5 for
entry in vitro (30, 31). We have reported that a vaginally
applied anti-gp120 mAb, b12, can protect macaques against
vaginal transmission of SHIV-162P4 (25).
We show that CMPD 167 has antiviral activity against
SIVmac251 and SIVB670 replication in vivo, by causing
marked, and sometimes sustained, reductions in plasma
viremia. However, even concentrations of CMPD 167 in
the millimolar range were generally unable to prevent vag-
inal transmission of SHIV-162P4, although they did reduce
the extent of viremia after infection. These results support
the development of CCR5 inhibitors as antiviral drugs.
They may also be useful as vaginal microbicides if they can
be successfully combined with other entry inhibitors.
 
Materials and Methods
 
Inhibition of SIVmac251, SIVB670, and SHIV-162P4 Replica-
tion In Vitro. 
 
Uncloned isolates of SIVmac251 (32), SIVB670
(33), and SHIV-89.6P (34) were provided by P.A. Marx, L. Mar-
tin (both affiliated with Tulane University, New Orleans, LA),
and N. Letvin (Harvard University, Boston, MA), respectively.
SHIV-162P4 was a gift from J. Harouse and C. Cheng-Mayer
(both affiliated with Rockefeller University, New York, NY)
(30, 31). Replication of test viruses in human and macaque PBMCs
in the presence and absence of CMPD 167 was determined as de-
scribed previously (29, 35).
 
Infusion of CMPD 167 into SIV-infected Macaques. 
 
Six adult
rhesus macaques (
 
Macacca mulatta
 
) of Indian origin ranging from 6
to 10 yr of age were infected with SIV for 116–293 d before
CMPD 167 therapy. Two macaques (AE55 and V744) had been
inoculated intravenously with SIVmac251 and four (T246, T682,
N217, and K299) had been inoculated intravaginally with
SIVB670. A seventh rhesus macaque of Chinese origin was inoc-
ulated intravenously with SHIV-89.6P (a CXCR4-using virus).
CMPD 167 (10 mg/kg in PBS) was administered intrave-
nously by bolus injection twice daily for 14 d and once daily for
an additional 14 d. Plasma viral loads were monitored 1–2 times
daily during treatment, and at least weekly for 6 wk after therapy
ceased. Plasma viral load was determined by quantifying SIV 
 
gag
 
RNA using a real-time RT-PCR assay (36). As used in the
present analysis, the assay has a sensitivity threshold of 60 RNA
copies/ml for all of the viruses tested, with an interassay co-
efficient variation of 
 
 
 
25%. CD4
 
 
 
 T cell counts were measured
using a whole-blood staining method and allophycocyanin-
conjugated anti-CD4 mAb RPA-T4 (Becton Dickinson). The
percentage of CD4
 
 
 
 T cells was determined by flow cytometry
using a FACSCalibur™ flow cytometer and CELLQuest™ soft-
ware, as described previously (36). Absolute numbers of lympho-
cytes were determined using a hematology analyzer system (Advia
120; Bayer Diagnostics, Inc). Absolute CD4
 
 
 
 T cell counts were
calculated by multiplying the percentage of lymphocytes that
were CD4
 
+
 
 by the absolute number of lymphocytes per microli-
ter of blood. All studies adhered to the Guide for the Care and
Use of Laboratory Animals, prepared by the National Research
Council, National Institutes of Health, and with the Guidelines
of the Tulane National Primate Research Center Institutional
Animal Care and Use Committee.
 
Vaginal Administration of CMPD 167 and Vaginal Challenge with
SHIV-162P4. 
 
Normal, cycling rhesus macaques 5–19 yr of age
were used. To thin the vaginal epithelium, macaques were
treated with a single 30-mg intramuscular injection of depo-
medroxyprogesterone acetate (Depo-Provera
 
®
 
; Pfizer) for 30–33 d,
as described previously (25). The macaques were sedated with
ketamine, placed in ventral recumbency, and 4–5 ml of either
2.5% hydroxymethyl cellulose (HMC) gel or CMPD 167 (0.6
mg/ml and 1 mM) in HMC was atraumatically introduced into
the vaginal vault using a pliable French catheter, followed 15 min
later by 300 TCID
 
50
 
 of SHIV-162P4 in 1 ml of RPMI 1640 me-
dium. Blood was collected weekly for at least 50 d. Plasma vire-
mia was quantified using either the bDNA assay (Bayer Diagnos-
tics Inc.) which has a sensitivity limit of 500 RNA copies/ml
plasma (see Fig. 4, top, challenge stock A), or by RT-PCR (sen-
sitivity limit, 60 RNA copies/ml) (see Fig. 4, bottom, challenge
stock B) as described in the preceding paragraph (37).
 
Data Analysis. 
 
In the treatment experiments, the viremic 
 
t
 
1/2
 
was calculated by fitting an exponential function to the data de-
rived either from the period from the viremia peak during acute
infection, or from the period between treatment initiation and the
first local minimum after the rapid decline. From the equation 
where M
 
0
 
 is the maximum viremia and T 
 
  
 
0, we derive 
 
t
 
1/2
 
 
 
 
 
(ln2)/
 
 
 
. In the microbicide studies, the effect of vaginal CMPD
167 administration on the extent of initial SHIV-162P4 replica-
tion was determined by comparing the maximum viral loads re-
12 ⁄ () M0e
λT – M0e
λ T t12 ⁄ + () –
, =T
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corded (log RNA copies/ml) in the control and CMPD 167 re-
cipient groups. For the two uninfected CMPD 167 recipients
(see Fig. 4, challenge stock A), the assay detection limit was con-
sidered to be the maximum value. We also compared the area
under the curve (AUC) of the log viral loads as a function of time
for the two groups. The AUC values were derived by approxi-
mating the curves to histograms describing the log RNA copies/
ml for the time intervals between days 0 and 35. For the two un-
infected animals, viral load was considered to be equal to the de-
tection limit (500 RNA copies/ml), rather than zero; this proce-
dure errs on the side of underestimating statistical differences
between the CMPD 167 and control groups. The Student’s 
 
t
 
 test
(one tail, unequal variance) included in Excel (Microsoft) was
used to assess the statistical significance of observed differences in
means between groups. Standard deviations given are for n 
 
  
 
1
degrees of freedom.
 
Results
 
CMPD 167 Is a Small Molecule CCR5 Inhibitor of SIV 
Replication In Vitro
 
A program at Merck Research Labs to identify new ways
to treat HIV-1 infection led to the development of the
CCR5 inhibitor CMPD 167 (Fig. 1), designated previously
MRK-1 (23, 24). CMPD 167 is a potent receptor antago-
nist for both human and macaque CCR5; it inhibits
chemokine ligand binding to macaque CCR5 with K
 
i
 
 val-
ues of 1 and 5 nM in buffer and whole blood, respectively.
Although it is not being developed for human use due to a
marginal therapeutic index (the highest concentration with
no adverse effect is 
 
 
 
10–30 mg/kg), the pharmacokinetic
profile of CMPD 167 in macaques renders it useful for eval-
uating the antiviral potential of CCR5 ligands in vivo (23).
First, we confirmed that CMPD 167 inhibits the replica-
tion of SIVmac251, SIVB670, and SHIV-162P4 in PBMCs
from different, uninfected macaques (Table I). Preinfection
PBMC samples from the SIV-infected test animals were
not available for this purpose because the animals were ac-
quired for this work only after they had already been in-
fected with SIV for other reasons. We have shown previ-
ously that the potency of a different small molecule CCR5
inhibitor, TAK-779, against SIVmac251 and SIVmac239 in
vitro varies considerably in a donor-dependent manner
(23). The same finding was made with CMPD 167, its 50%
inhibitory concentration (IC
 
50
 
) values against SIVmac251
and SIVB670 varying throughout a 
 
 
 
250-fold range in
PBMCs from different macaques (Table I). Whatever the
IC
 
50
 
 value, high concentrations of CMPD 167 (up to 10
 
 
 
M) caused complete or almost complete (i.e., 
 
 
 
90%) in-
hibition of the replication of the test viruses in cells from
most, but not all, of the donor macaques (Table I), similar
to what was observed using TAK-779 (23).
CMPD 167 also inhibited HIV-1 replication in human
PBMCs, with IC
 
50
 
 values usually in the low nanomolar
range (Table I). The range of IC
 
50
 
 values for this and other
CCR5 inhibitors was much less in human than in macaque
PBMCs (Table I and not depicted). We have observed this Figure 1. Structure of the CCR5 inhibitor, CMPD 167.
 
Table I.
 
Inhibition of SIV, SHIV and HIV-1 Replication by 
CMPD 167 In Vitro
 
Virus
PBMC 
type Donor IC
 
50
 
Max
Inhibition
 
nM %
 
SIVmac251 macaque A 130 91
B8 5 7 7
C 8.0 100
D3 6 9 6
E 0.47 100
SIVB670 macaque B 9.3 55
C 5.3 98
SHIV-162P4 macaque A 61 86
B 3.4 100
C 5.2 100
F 30 100
SHIV-89.6P macaque G
 
 
 
10,000 –
H
 
 
 
10,000 –
SHIV-162P4 human I 0.030 100
J 0.24 98
HIV-1 JR-FL human I 0.27 100
J 0.20 97
HIV-1 CC1/85 human I 0.31 100
J 0.15 100
IC
 
50
 
 values derived from individual experiments using PBMC from
different uninfected macaques (A–H ) or humans (I and J) are pre-
sented, along with the maximum percentage inhibition achieved with
higher concentrations of CMPD 167 (up to 10 
 
 
 
M). Macques A–H do
not correspond to animals described in Figs. 2–4.T
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with small molecule CCR5 inhibitors in general. SHIV-
162P4 replication was also inhibited by CMPD 167 in both
human and macaque PBMCs, again to a variable extent
(Table I). However, the extent of the variation in SHIV-
162P4 sensitivity in macaque PBMCs was less than ob-
served with SIVmac251 and SIVB670. CMPD 167 did not
inhibit SHIV-89.6P replication in macaque PBMCs (Table
I), although this virus was sensitive to the CXCR4-specific
inhibitor AMD3100, with IC
 
50
 
 values 
 
 
 
1 nM (23) (not
depicted). Hence, as concluded previously from studies us-
ing TAK-779, SHIV-89.6P behaves as an X4 virus in
macaque PBMCs, with no detectable sensitivity to CCR5-
specific inhibitors (30).
We again interpret these observations to mean that
CCR5 is the paramount coreceptor used by SIVmac251
and SIVB670 to enter macaque PBMCs in vitro (30).
However, unknown factors significantly influence the effi-
ciency of action of CCR5-targeted inhibitors in these cells,
more than in human PBMCs. A more extensive analysis is
now in progress to understand this variation.
 
Treatment of SIV-infected Rhesus Macaques with CMPD 167
 
Six rhesus macaques of Indian origin infected with un-
cloned SIV isolates were monitored for 116–240 d until a
stable viral set point was achieved. Some of the test animals
were obtained only very shortly before therapy was com-
menced, limiting the amount of pretherapy viral load data
that could be obtained.
To ensure consistency in dosing and to minimize ani-
mal-to-animal variability in pharmacokinetic profiles, we
elected to deliver CMPD 167 by intravenous infusion. Ex-
cept for animal K299, the monkeys received 10 mg/kg of
CMPD 167 twice daily for 14 d followed by a switch to
once-daily dosing for a further 14 d, to reduce the cumula-
tive stress on the animals caused by drug infusion under an-
esthesia. This regimen provided the maximum possible re-
Figure 2. Effect of CMPD
167 infusion into macaques in-
fected with SIVmac251, SIVB670,
or SHIV-89.6P. Twice-daily
CMPD 167 therapy was com-
menced on day 0 (indicated by
vertical line). After 14 d, therapy
was administered once daily
(arrowhead,  1X) for an addi-
tional 14 d, until day 28, when
treatment  was stopped (arrow-
head, END). The dotted line
indicates the viral load “baseline”
at the time therapy was initiated.
Each panel represents the study
of an individual macaque.T
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ceptor coverage while staying acceptably below the toxic
level of CMPD 167 for macaques. The peak concentration
of CMPD 167 in macaque plasma during twice-daily dos-
ing is 
 
 
 
15 
 
 
 
M. Because the plasma half life of CMPD 167
is 
 
 
 
2 h, this dosing regimen maintained a trough concen-
tration of 
 
 
 
70 nM (at 12 h), which is 
 
 
 
90% inhibitory
concentration value for inhibiting the binding of chemo-
kines to human and macaque CCR5 (reference 30; unpub-
lished data). The trough level is also above the IC
 
50
 
 value
for inhibition of SIV replication in PBMCs from some of
the uninfected donor macaques (Table I). However, this
concentration may not be sufficient to completely block
SIV replication in all the infected animals if the variation in
their sensitivity to CMPD 167 is similar to that observed in
vitro using PBMCs from different, uninfected macaques
(Table I). After the change to once-daily dosing, the
trough concentration of CMPD 167 in plasma (5–10 nM at
24 h) approximates the IC
 
50
 
 value for inhibition of
chemokine binding in vitro (24). This concentration is un-
likely to be high enough to completely block macaque
CCR5, particularly in any animals whose cells are at the
less sensitive end of the range observed in vitro (Table I).
Thus, some SIV entry via CCR5 is to be expected over
part or all of the dosing cycle in some of the test animals.
The administration of CMPD 167 caused rapid, expo-
nential reductions in plasma viremia in all six SIVmac251-
or SIVB670-infected animals, as discussed further in the
next section (Fig. 2). Significant declines in viral load were
detectable within 24 h, with an initial nadir being reached
after 3–6 d. At the nadir, the viral load reduction from the
pretherapy value varied from 4- to 200-fold in different an-
imals; the mean was 55-fold (Fig. 2 and Table II). The
mean 
 
t
 
1/2
 
 for the viral load decline was 0.94 
 
 
 
 0.18 d, sig-
nificantly shorter than the corresponding value for the de-
cline during primary infection in the same animals (6.4 
 
 
 
2.7 d) (Table II, P 
 
 
 
 0.0020, Student’s 
 
t
 
 test). Hence, the
drug-induced decline in viral load was rapid with little
variation between animals.
We also studied the effect of CMPD 167 on viral load in-
duced by SHIV-89.6P, to see whether the lack of sensitivity
of this virus to this inhibitor in vitro (Table I) was also true
in vivo. Because SHIV-89.6P is highly aggressive and usu-
ally causes very rapid disease progression in macaques of In-
dian origin (38, 39), we used a macaque from China. Viral
loads are generally lower and the disease course slower in
these animals (39). We also elected to begin therapy of the
SHIV-89.6P–infected animal, M244, on an earlier day after
infection (day 55) than for the SIV-infected animals, to
minimize the chances of it progressing to disease before the
end of our work. The pretherapy viral load in M244 had
not fully stabilized by day 55, as shown by the markedly
downward slope of the viremia plot in the period immedi-
ately before CMPD 167 was infused. In contrast, the viral
loads in the SIV-infected animals T246 and T682 were
slowly rising in the last 40 d before therapy, and in V744
and AE55, they were slowly falling (minimal pretherapy
data were available from animals N217 and K299).
CMPD 167 had a negligible effect on plasma viral load
in M244 (Fig. 2). Indeed, the viral load marginally in-
creased in the first 5 d of therapy, leading to a twofold re-
 
Table II.
 
Summary of the Outcome of CMPD 167 Infusion into Different Macaques Infected with SIVmac251, SIVB670, or SHIV89.6P
 
Animal V744 AE55 T246 T682 N217 K299 M244
Virus SIVmac251 SIVmac251 SIVB670 SIVB670 SIVB670 SIVB670 SHIV89.6P
Start of therapy (days after challenge) 116 116 240 240 240 132 55
 
t
 
1/2
 
 (days) for VL decline in primary
infection, [R
 
2
 
] 10 [0.90] 5.3 [0.84] 2.9 [0.82] 5.2 [0.78] 8.8 [0.78] 5.9 [0.59] 3.7 [0.69]
VL at start of therapy (RNA copies/ml) 1.3 
 
  
 
10
 
6
 
2.9 
 
  
 
10
 
5
 
1.1 
 
  
 
10
 
6
 
4.4 
 
  
 
10
 
4
 
2.3 
 
  
 
10
 
6
 
1.4 
 
  
 
10
 
6
 
6.2 
 
  
 
10
 
3
VL at initial treatment-induced nadir 
(RNA copies/ml) a5.6   104a 7.0   104 1.1   105 5.5   103 2.1   105 7.1   103 NAe
Fold reduction in VL at initial nadir 23 4 10 80 11 200 7
Time to reach nadir (days) 3.5 4 3 7 4 6 NAe
t1/2 (days) for VL decline to initial 
treatment-induced nadir, [R2] 0.70 [0.93] 1.1 [0.82] 0.89 [0.98] 1.1 [0.95] 1.1 [0.96] 0.77 [0.96] 7.4 [0.27]f 
VL reboundb  (days from end of treatment) 43 2 36 29  14c NAd NA 
R2 describes the fit of the exponential function to the data. A value  0.25 indicates a good correlation with the logarithmically transformed linear
function. NA, Not applicable. 
aLower values were recorded subsequently; the lowest value for AE55 was 1.1   104 RNA copies/ml on day 21; for V744, 1.9   104 on day 17. 
bRebound indicates the number of days from the end of CMPD 167 treatment until viral load met or exceeded the pretreatment, baseline value.
cRebound occurred 14 d before the end of therapy, not after it. 
dThis animal was removed from the study after 10 d of therapy.
eA full description is provided on the next page.
fAlthough no treatment effect was detectable, t1/2 for the spontaneous VL decline was measured over the relevant period.T
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duction in the slope of the viral load plot (Fig. 2 and Table
II). In contrast, the viral load plots in the SIV-infected ani-
mals T246, T682, V744, and AE55 all showed a steep,
downward slope in the first 5 d after CMPD 167 infusion
that was  10-fold steeper than the corresponding prether-
apy slope. The much poorer fit of an exponential function
to the viral load after treatment in M244 than for the SIV-
infected animals also suggests that M244 alone did not un-
dergo a drug-induced reduction in viremia (Table II). Viral
loads fluctuated only moderately in M244 during therapy,
with no clear downward trend over and above the natural
decline that was in progress before therapy (Fig. 2). Fur-
thermore, when therapy was stopped, there was no viral
load rebound. Hence we conclude that a CCR5 inhibitor
has a negligible effect on SHIV-89.6P replication in
macaque cells in vivo, just as it does in vitro (Table I).
SHIV-89.6P is functionally an X4 virus (30). Moreover,
the lack of effect of CMPD 167 on SHIV-89.6P replication
suggests that the viral load declines in the SIVmac251- and
SIVB670-infected animals were not attributable merely to
the infusion of the inhibitor under anesthesia.
The Viral Load Responses to CMPD 167 Infusion in
Individual Macaques 
All six SIV-infected animals responded differently to
CMPD 167 infusion (Fig. 2).
Macaque V744 (SIVmac251 Infected).  A significant
drop in viremia from the baseline value of 1.3   106 RNA
copies/ml was detectable within 36 h, and a nadir of
56,000 copies/ml, a 23-fold decline, was reached after 3.5 d.
Viral load rebounded slightly, fluctuating in the range
19,000–390,000 copies/ml for the remainder of the treat-
ment period, even after the switch to once-daily dosing.
Indeed, the lowest plasma viremia level (19,000 copies/ml)
occurred 2 d after the dosing reduction. Viremia was
160,000 copies/ml when therapy ended. It remained sup-
pressed at close to that level for a further 21 d, before
steadily rebounding to reach values from 106 to 2   106
copies/ml by 5–8 wk after the end of therapy.
Macaque AE55 (SIVmac251 Infected).  Baseline viral
load was 290,000 RNA copies/ml. A decline was detected
after 2 d, and a nadir of 70,000 copies/ml was reached after
4 d, a 4.1-fold decline. Viremia hovered from 110,000 to
190,000 copies/ml for the next 10 d, before declining again
(coincidentally or otherwise) to fluctuate from 11,000 to
370,000 copies/ml, during the period of halved CMPD 167
dosage. The nadir during that period, 11,000 copies/ml,
was 26-fold below baseline, but viral load gradually re-
bounded. The viral load after therapy was from 150,000 to
430,000 copies/ml for 8 wk, similar to the pretherapy value.
Macaque T246 (SIVB670 Infected).  The baseline viral
load of 1.1   106 RNA copies/ml dropped by 10-fold to
110,000 copies/ml within 3 d. Viremia remained fairly
steady in the range 130,000–350,000 copies/ml until ther-
apy was discontinued after 27 d, when it was 200,000 cop-
ies/ml. There was no evidence of any viral load rebound
during therapy, but a transient, partial increase to 750,000
copies/ml took place 5–11 d after the end of therapy. By
day 22 after therapy, viral load was 450,000 copies/ml, ap-
proximately twice the level on the day of discontinuation.
Viremia rebounded fully over the next 2 wk, eventually
reaching 1.5   106 copies/ml 36 d after the end of therapy,
similar to the pretherapy level.
Macaque T682 (SIVB670 Infected).  A rapid, 80-fold
decline in plasma viremia from a baseline level of 440,000
RNA copies/ml to a nadir of 5,500 copies/ml occurred
during the first 7 d. A slow but steady rebound to 62,000
copies/ml took place over the next 8 d, after which, the vi-
ral load gradually, but slightly, declined again. Viral load
was 32,000 copies/ml at the end of therapy, 14-fold below
baseline. A gradual rebound was detectable within 3–5 d,
and viremia steadily increased thereafter, reaching 750,000
copies/ml by 36 d after the end of therapy, 1.7-fold higher
than baseline.
Macaque N217 (SIVB670 Infected).  The response of
this animal to CMPD 167 was unusual. Within 4 d, vire-
mia had dropped by 11-fold from the baseline value of
2.3    106 to a nadir of 210,000 copies/ml. A modest,
short-lived, transient blip occurred over the next 5 d, but
viremia was still depressed (280,000 copies/ml) on day 9 of
therapy. However, a strong rebound was seen during the
next 10 d, viremia rising as high as 1.1   107 copies/ml by
day 21, fivefold above the pretherapy value. A further de-
cline took place over the remaining 4 d, so that the level of
viremia at the end of therapy (2.6   106 copies/ml) was al-
most the same as the pretherapy value (2.3   106 copies/ml).
Viral load did not increase after therapy was discontinued;
indeed, 36 d later, plasma viremia (940,000 copies/ml) was
2.8-fold lower than on the day therapy was stopped.
Macaque K299 (SIVB670 Infected).  This animal was in-
cluded in the work despite its availability on short notice. A
limited amount of information could be obtained as K299
became ill and died after 10 d of therapy from “fatal fasting
syndrome,” which is a common disease of obese macaques
(40). The death was unrelated to CMPD 167 infusion. The
viral load at the onset of therapy (1.4   106 RNA copies/
ml) declined very rapidly after CMPD 167 was infused,
Figure 3. Absolute CD4  T cell counts in the blood of three SIV-infected
macaques before, during, and after treatment with CMPD 167. The pre-
treatment values shown were determined 164–184 d before therapy (84–
104 d after infection).T
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halving within 24 h, and reached a nadir of 7,100 copies/
ml (a 200-fold decline) within 6 d. A partial rebound to
90,000 copies/ml had occurred by the time the animal died
after a further 4 d.
CD4 T Cell Responses to CMPD 167
CD4  T cell counts were measured in three of the test
animals (N217, T246, and T682) before and during the
course of CMPD 167 therapy (Fig. 3). Because we were
examining viral loads twice daily in the initial studies, in-
sufficient blood volumes were available for CD4 counts to
be measured for the other three animals. There was a
marked, two- to threefold increase in the CD4  T cell
count in T246 and T682 within 7 d of therapy that coin-
cided with the initial decrease in viral load, followed by a
partial decline (Figs. 2 and 3). In N217, the initial increase
in the CD4  count occurred more slowly, peaking after 21 d
at approximately twice the pretherapy level (Fig. 3). In all
three macaques, the CD4  T cell count was greater at the
end of CMPD 167 therapy than at the beginning, and it
was still elevated 35 d later (Fig. 3).
Evaluating CMPD 167 for Its Ability to Prevent the Vaginal 
Transmission of an R5 SHIV
We also studied whether CMPD 167 could be used as a
topical microbicide to prevent the vaginal transmission of
SHIV-162P4 to uninfected macaques (20, 21). SHIV-
162P4 rarely causes sustained plasma viremia; the usual pat-
tern is a transient, high level of replication followed by a
decline to minimal viremia levels by 5–8 wk (25). Hence,
we are using this virus only to determine whether a candi-
date microbicide can have a short-term protective effect
against virus transmission and/or its early replication.
In preliminary experiments, saline solutions of CMPD
167 in the micromolar or low millimolar range failed to
protect any macaques against SHIV-162P4 (unpublished
data). Therefore, we formulated CMPD 167 in 2.5% HMC
gel at 0.6 mg/ml ( 1 mM) and applied 5 ml to the vagina
of each test macaque, followed by vaginal SHIV-162P4
challenge 15 min later. HMC gel itself had no protective ef-
fect compared with saline (unpublished data). Moreover,
we confirmed that in vitro formulation in HMC gel did not
interfere with the antiviral activity of CMPD 167 in either
human or macaque PBMCs (unpublished data).
In two experiments involving a total of 20 macaques and
two different SHIV-162P4 challenge stocks, we saw lim-
ited evidence of full protection by CMPD 167 when the
data were pooled and analyzed. Thus, all 9 animals that re-
ceived HMC gel alone became infected, as did 9 of 11 ani-
mals given CMPD 167 in HMC (Fig. 4). The difference in
the infection rate between the two groups was not signifi-
cant. However, plasma viremia after infection was signifi-
cantly less, on average, in the CMPD 167 group than in
the control group. The mean peak log viral load values
were lower (4.4   1.1) for the CMPD 167 recipients than
in the HMC controls (6.1   0.93) (P   0.0011). An ap-
Figure 4. After the infection, viral loads
in macaques were challenged vaginally with
SHIV-162P4 after vaginal administration of
HMC gel or CMPD 167 formulated in
HMC at  1 mM. Two separate, but similar,
experiments are shown, each performed using
a different SHIV-162P4 challenge stock and
a different method of quantifying viral RNA.
Hence, the results are plotted separately.T
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proximation of cumulative plasma viremia was also esti-
mated by calculating the mean AUC ( SD) for log RNA
copies per ml as a function of time over the first 35 d after
challenge. The AUC also was significantly lower for the 11
CMPD 167 recipients (120   22) than for the 9 control
animals (150   25) (P   0.0080).
Discussion
We have studied how a small molecule, a CCR5-spe-
cific inhibitor, affects SIV replication in vivo. Although
CMPD 167 is not now being developed as an antiviral
drug, similar CCR5 inhibitors are (41). The initial rate of
viral load decline in response to CMPD 167 (t1/2, 0.94  
0.18 d) was as fast as rates observed during protease inhibi-
tor monotherapy in humans (42, 43), and comparable to
that induced by the combination of Tenofovir and  -2 ,3 -
dideoxy-3 -thia-5-fluorocytidine in one of two SIV-infected
pig-tailed macaques (44). Direct comparisons involving dif-
ferent test viruses and species are difficult, but CMPD 167
clearly has significant antiviral activity in vivo.
There was considerable variation in the responses of in-
dividual animals to CMPD 167. The mean viremia re-
duction at the initial nadir was 55-fold but ranged from
4.1-fold (AE55) to 200-fold (K299). Moreover, the level of
residual viral replication in each test animal was both
substantial and variable, with nadir values from 5,500 to
200,000 RNA copies/ml (Table II). Neither the rate nor
the extent of the initial decline was correlated with the viral
load at the onset of therapy (4.4   104 to 2.3   106 RNA
copies/ml), rather higher than usually found in HIV-1–
infected humans (39, 42, 43). One plausible explanation for
animal-to-animal variation is that it is related to factors that
influence the antiviral potency of CMPD 167 and another
CCR5 inhibitor, TAK-779, in vitro (Table I; reference 29).
Clearly, if the IC50 for inhibition of SIV replication in vivo
spanned the 275-fold range (0.47–130 nM) observed in
PBMCs from different, uninfected macaques in vitro, a con-
siderable variation in viral load reduction would be expected.
With predicted trough levels of 70 nM during the twice-daily
dosing phase, lower during once-daily dosing, plasma drug
levels may simply not have been high enough to substantially
inhibit SIV replication in some of the animals. Unfortunately,
because the macaques were only acquired after they had been
infected with SIV, we could not study the inherent sensitivity
of their PBMCs to CMPD 167 before commencing therapy.
Future studies will be designed accordingly.
The molecular mechanisms underlying animal-to-animal
variation in response to CMPD 167 are unclear. Differ-
ences in the levels of CCR5 expression on the target cells
of different animals, or in the extent of CC-chemokine se-
cretion, could affect the potency of any CCR5 inhibitor
(41, 45–52). The variable responses could also reflect the
use by SIV of alternative coreceptors (such as BOB,
CXCR6, etc.), which would be insensitive to CMPD 167.
The expression levels of these potential coreceptors on var-
ious cell types is host dependent (53).
Factors applying only under in vivo conditions could
also influence how different macaques responded to
CMPD 167. Animal-to-animal differences in pharmaco-
kinetics could be relevant, although we deliberately used
intravenous dosing to minimize such variation. Drug levels
may be lower in the lymphoid compartments, where SIV
replicates, than in the plasma. Due to the toxicity profile of
CMPD 167, we were not able to perform dose-escalation
studies. Finally, although all the macaques were infected
with SIVmac251 or the related SIVB670 virus, host im-
mune responses are likely to create viral diversity during
the period between infection and the onset of therapy;
therefore, partially resistant viruses could be present in
some animals. Additional studies, some now commenced,
will be required to resolve these questions.
Many of these factors might also apply to understanding
variation in the antiviral effects of CCR5 inhibitors in hu-
mans (13, 14). Host-dependent variable responses have
been observed in early human trials of SCH-C; viral load
declines after 10-d dosing varied from 0 to  1.5 log in dif-
ferent individuals all infected with SCH-C–sensitive R5
HIV-1 isolates (13, 14). Extrapolations from SIV-infected
macaques to HIV-1–infected humans are problematic, but
the use of alternative coreceptors by HIV-1 is much less
common than by SIV, at least in vitro (28, 29, 53–56).
Hence, alternative coreceptor usage may not contribute to
the variable responses to CCR5 inhibitors in humans, and
it is only one possible explanation of what we observed in
the macaques.
A notable observation was that animals V744 and T246
had no detectable plasma viremia rebound throughout the
28 d of CMPD 167 therapy despite high residual viral loads
of 105–106 RNA copies/ml. Hence, SIV might not be able
to generate escape mutants easily in response to a CCR5
inhibitor, at least in some infected animals. In vitro, the de-
velopment of HIV-1 escape mutants in response to differ-
ent small molecule CCR5 inhibitors is a slow and complex
process requiring the accumulation of multiple sequence
changes in gp120, without coreceptor switching to CXCR4
(reference 35; unpublished data). Switching to CXCR4 use
as an escape pathway is probably less likely with SIV than
HIV-1. However, plasma viremia did rebound rapidly dur-
ing therapy of animal N217, rapidly but only partially in
T682, and slowly in AE55 (Fig. 2). Indeed, in N217, there
was a net increase in viral load during the third week of ther-
apy, and the increase in CD4  T cell count in N217 was de-
layed compared with animals T246 and T682 (Fig. 4). We
are now investigating whether a CMPD 167 escape mutant
developed in N217 within the first 5–10 d of therapy that
was not just resistant to the inhibitor but that was also able to
briefly replicate in a new population of target cells, perhaps
because of a change in coreceptor usage. In principle, this
could have adverse pathogenic consequences. However, the
upward spike in virus replication was temporary; viral load in
N217 had dropped back to baseline by the time therapy was
discontinued and continued to decline modestly, so what-
ever occurred was a transient event.T
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The viremia rebound in animal T682 during therapy was
only partial, but it was notable that when therapy was
stopped, viral load returned to baseline rather more rapidly
than it did in V744 and T246. Partially resistant mutant vi-
ruses may have developed during therapy in T682, and also
in AE55. Genotypic and phenotypic studies of the viral
strains present in the test animals before, during, and after
CMPD 167 therapy are now underway.
A particularly unexpected finding was that, in V744, no
rebound in viremia occurred for 3 wk after CMPD 167
therapy ceased; only later did viremia rise gradually to the
baseline level. Furthermore, in T246, full rebound to the
pretherapy level only took place 22–36 d after the end of
therapy. When conventional highly active antiretroviral
therapy is discontinued in humans, viral load usually re-
bounds within  7–14 d, even from levels  500 RNA
copies/ml (57, 58). In macaques V744 and T246, plasma
viremia at the end of CMPD 167 therapy was much higher
(up to 2   106 and 1.5   106 RNA copies/ml, respec-
tively), yet the rebound was still markedly delayed. There-
fore, a CCR5 inhibitor can have a sustained effect on viral
replication after therapy is stopped, at least in some test an-
imals. Delays of a few days before viremia rebounded after
the completion of a 10-d dosing protocol have also been
observed in some HIV-1–infected patients during early hu-
man trials of SCH-C (13). Hence, whatever happened in
animal V744 might not be unique to SIV infection of a
monkey. We are now investigating whether CMPD 167
and other CCR5 inhibitors can have a sustained effect on
the expression and recycling of functional CCR5 receptors
in macaque and human PBMCs.
In summary, CMPD 167 monotherapy caused a rapid
decrease in viremia in all 6 SIV-infected animals, and an in-
crease in CD4  T cell count in all three animals in which
this was measured. The reduced viral load could be main-
tained throughout the 28 d of therapy (and sometimes well
beyond) in some monkeys, even in the face of high viral
replication and despite reducing CMPD 167 input to what
may have been suboptimal levels. Together with early
evidence of other CCR5 inhibitors being effective in
HIV-1–infected humans (13) (C. Hitchcock, personal com-
munication), these findings should encourage the practical
development of CCR5 blockers as antiviral drugs. These
compounds should be combined with other entry inhibi-
tors or more conventional antiviral drugs, based on in vitro
studies (11–15, 17, 59, 60).
We also evaluated whether CMPD 167 could prevent
vaginal transmission of the R5 virus SHIV-162P4. The use
of a SHIV rather than a SIV permitted comparison of
CMPD 167 with other compounds specific for the HIV-1
envelope glycoproteins, such as the anti-gp120 mAb b12,
which can protect macaques against vaginal transmission of
SHIV-162P4 (25). We found that CMPD 167, delivered
vaginally at 1 mM in HMC gel, was not consistently pro-
tective. Hence, a CCR5-specific compound that inhibits
SHIV-162P4 replication in the nanomolar range in vitro
was ineffective against the same challenge virus in vivo,
even when used at a million-fold higher concentration.
mAb b12 could only protect macaques against SHIV-
162P4 when applied vaginally at 1 mg/ml, a concentration
100- to 1,000-fold more than neutralized the same virus in
vitro (25). Clearly, the quantitative aspects of achieving
protection using a CCR5-specific inhibitor are even more
daunting. A higher concentration of CMPD 167, or a dif-
ferent formulation of it, might be more effective, but 1
mM was the highest concentration we could achieve at
neutral pH.
It is possible that a topically applied small molecule
CCR5 inhibitor cannot be fully effective against vaginal (or
rectal) transmission, because it may not penetrate to the
sites where CCR5-mediated fusion occurs during the early
stages of infection. These events may happen at or close to
the vaginal epithelium where a CCR5 inhibitor could in-
tervene (61–65). However, an alternative or additional
route of transmission involves transport of virus to lymph
nodes within dendritic cells, where it only fuses with
CD4  CCR5  T cells upon arrival (63, 64, 66, 67). If so, a
topically applied, receptor-blocking compound has little
chance to intervene successfully when used alone. We did
observe partial protection in that viral load after infection
was reduced in the CMPD 167 recipients. The simplest ex-
planation is that CMPD 167 successfully prevented the
transmission of some of the virus particles that normally es-
tablish infection, thereby diminishing SHIV-162P4 replica-
tion during primary infection. However, other routes of
transmission remained unimpeded.
The goal of a microbicide must be to fully prevent the
establishment of infection; a modest reduction in viral load
after infection would not be of significant benefit. In that
sense, the results obtained with CMPD 167 are not en-
couraging. However, the SHIV-162P4 inoculum used to
challenge the progesterone-treated macaques is  108 RNA
copies/ml, sufficient to cause infection of almost 100% of
the test animals (25). Therefore, this model is a stringent
test of a vaginal microbicide. The infectious HIV-1 dose
for women is not known, so it is hard to predict how
CMPD 167 would fare in naturally exposed women, given
the many complex assumptions that must be made. How-
ever, it is reasonable to assume that the lower the inoculum
to be countered, the easier the task for a receptor-blocker
(25, 41). Combinations of entry inhibitors that include a
CCR5-specific small molecule should, therefore, be fur-
ther evaluated in macaques (25, 59). CCR5 inhibitors that
act differently from CMPD 167 (i.e., a chemokine deriva-
tive that caused sustained CCR5 down-regulation) should
also be pursued (52, 68).
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